Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.65 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.65 |
| ▸ | PRKCA | P17252 | 1/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.60 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397697 | 1.00 | DGKA (0.68) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL12438321 | 1.00 | DGKA (0.68) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL10655057 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL332986 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL2396742 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL12438334 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL3658169 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL9169298 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL332985 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA | |
| SCHEMBL9169289 | 0.97 | DGKA (0.73) | DGKAPRKCEPRKCQPRKCDPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20160024012-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-28 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-12-31 | — | — | US | disclosed |
| US-8536328-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-09-17 | — | — | US | disclosed |
| US-8431576-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-04-30 | — | — | US | disclosed |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LIMITED | 2013-04-18 | — | — | US | disclosed |
| US-8366819-B2 | Oily inkjet ink | RISO KAGAKU CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | ALKERMES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110275803-A1 | PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS | ALKERMES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110232528-A1 | OILY INKJET INK | RISO KAGAKU CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | DGKA 2661/4885PRKCE 2537/4885PRKCQ 2469/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | DGKA 2661/4885PRKCE 2537/4885PRKCQ 2469/4885 |
| US-20130096089-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | DGKA 3156/4885PRKCE 3671/4885PRKCQ 3607/4885 |
| US-20160024012-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | DGKA 2661/4885PRKCE 2537/4885PRKCQ 2469/4885 |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DGKA 4304/4885PRKCE 3622/4885PRKCQ 3930/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DGKA 4304/4885PRKCE 3622/4885PRKCQ 3930/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DGKA 4304/4885PRKCE 3622/4885PRKCQ 3930/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | DGKA 2898/4885PRKCE 3696/4885PRKCQ 2431/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DGKA 3156/4885PRKCE 3671/4885PRKCQ 3607/4885 |
| US-20110275803-A1 | PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS | COASY, DHPS, OXA1L | DGKA 2661/4885PRKCE 2537/4885PRKCQ 2469/4885 |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | DGKA 3222/4885PRKCE 4369/4885PRKCQ 4491/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DGKA 4304/4885PRKCE 3622/4885PRKCQ 3930/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | DGKA 3222/4885PRKCE 4369/4885PRKCQ 4491/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | DGKA 3156/4885PRKCE 3671/4885PRKCQ 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.